Beneficial Effect of Silymarin in Ulcerative Colitis

Launched by TANTA UNIVERSITY · Jan 18, 2024

Keywords

ClinConnect Summary

This clinical trial is studying whether a supplement called silymarin can help improve the condition of adults with Ulcerative Colitis (UC) who are already being treated with a medication called mesalamine. The trial will involve 44 participants who will be divided into two groups. One group will receive mesalamine along with another medication, azathioprine, while the second group will receive the same medications plus silymarin for three months. The main goal is to see if adding silymarin leads to a noticeable improvement in their symptoms.

To participate, individuals must be between 18 and 65 years old and have a confirmed diagnosis of Ulcerative Colitis. They also need to be in good health regarding their kidney and liver functions and must be willing to give their consent to join the study. Throughout the trial, participants will be closely monitored to track any changes in their condition. It's also important to note that certain individuals, such as those with serious health issues, pregnant or breastfeeding women, and smokers, will not be eligible to participate. This trial is currently recruiting participants at specific hospitals in Assiut, Egypt.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Adults of both sexes aged from 18 years to 65 years.
• • 2. Adults with normal kidney and liver functions.
• • 3. Patients who sign the consent and willing to participate in the study.
• • 4. Patients with UC according to American College of Gastroenterology Clinical Guidelines for diagnosis Ulcerative Colitis having clinical signs and symptoms with a completed medical workup, colonoscopy, pathological and laboratory data confirming UC
• Exclusion Criteria:
• • 1. Previous hypersensitivity or anaphylactic reaction to silymarin.
• • 2. Significant renal and hepatic impairment.
• • 3. Patients who refuse to participate.
• • 4. Pregnant women, breastfeeding women and smokers.
• • 5. Patients taking corticosteroids or biological therapy.
• • 6. Patients taking any other antioxidants.
• • 7. Patients having other concomitant diseases where oxidative stress is involved in the etiology such as chronic liver disease, pulmonary infection.